Reading Time: 3 minutesIntroduction Osteoarthritis, a degenerative joint disease, is a prevalent condition among American males, often resulting in significant morbidity and reduced quality of life. Hypogonadism, characterized by low testosterone levels, has been identified as a contributing factor to the development and progression of osteoarthritis. Delatestryl, a testosterone enanthate injection manufactured by Endo Pharmaceuticals, has emerged as a potential therapeutic option for hypogonadal males. This article evaluates the role of Delatestryl in reducing the risk of osteoarthritis in this population, focusing on its efficacy, safety, and clinical implications. Efficacy of Delatestryl in Reducing Osteoarthritis Risk Clinical studies have demonstrated that testosterone replacement … Continue reading →